It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
ADP-ribosylation is integral to a diverse range of cellular processes such as DNA repair, chromatin regulation and RNA processing. However, proteome-wide investigation of its cellular functions has been limited due to numerous technical challenges including the complexity of the poly(ADP-ribose) (PAR) chains, low abundance of the modification and lack of sensitive enrichment methods. We herein show that an adenosine analogue with a terminal alkyne functionality at position 2 of the adenine (2-alkyne adenosine or 2YnAd) is suitable for selective enrichment, fluorescence detection and mass spectrometry proteomics analysis of the candidate ADP-ribosylome in mammalian cells. Although similar labelling profiles were observed via fluorescence imaging for 2YnAd and 6YnAd, a previously reported clickable NAD+ precursor, quantitative mass spectrometry analysis of the two probes in MDA-MB-231 breast cancer cells revealed a significant increase in protein coverage of the 2YnAd probe. To facilitate global enrichment of ADP-ribosylated proteins, we developed a dual metabolic labelling approach that involves simultaneous treatment of live cells with both 2YnAd and 6YnAd. By combining this dual metabolic labelling strategy with highly sensitive tandem mass tag (TMT) isobaric mass spectrometry and hierarchical Bayesian analysis, we have quantified the responses of thousands of endogenous proteins to clinical PARP inhibitors Olaparib and Rucaparib.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Imperial College London, South Kensington Campus, Department of Chemical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Durham University, Department of Chemistry, Durham, UK (GRID:grid.8250.f) (ISNI:0000 0000 8700 0572)
2 Imperial College London, South Kensington Campus, Department of Chemical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Helmholtz Zentrum München, Institute of Functional Epigenetics, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
3 The Francis Crick Institute, Mass Spectrometry Proteomics Platform, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
4 Bloomberg School of Public Health, Johns Hopkins University, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
5 National Heart & Lung Institute, Vascular Science Section, Hammersmith Campus, Faculty of Medicine, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
6 Imperial College London, South Kensington Campus, Department of Chemical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)